315 related articles for article (PubMed ID: 37686121)
21. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
22. Vascular endothelial growth factor-D: signaling mechanisms, biology, and clinical relevance.
Achen MG; Stacker SA
Growth Factors; 2012 Oct; 30(5):283-96. PubMed ID: 22817635
[TBL] [Abstract][Full Text] [Related]
23. Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis.
Eroğlu A; Ersöz C; Karasoy D; Sak S
Adv Clin Exp Med; 2017; 26(2):245-249. PubMed ID: 28791841
[TBL] [Abstract][Full Text] [Related]
24. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression.
Choi WW; Lewis MM; Lawson D; Yin-Goen Q; Birdsong GG; Cotsonis GA; Cohen C; Young AN
Mod Pathol; 2005 Jan; 18(1):143-52. PubMed ID: 15297858
[TBL] [Abstract][Full Text] [Related]
25. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
Takahashi S
Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Variances in VEGF-A-D and VEGFR-1-3 Expression in the Ishikawa Endometrial Cancer Cell Line Treated with Salinomycin and Anti-Angiogenic/Lymphangiogenic Effect.
Kras P; Talkowski K; Grabarek BO; Skalska-Dziobek N; Boroń D; Oplawski M
Curr Pharm Biotechnol; 2021; 22(5):697-705. PubMed ID: 32648839
[TBL] [Abstract][Full Text] [Related]
27. Primary Tumor-Secreted Lymphangiogenic Factors Induce Pre-Metastatic Lymphvascular Niche Formation at Sentinel Lymph Nodes in Oral Squamous Cell Carcinoma.
Wakisaka N; Hasegawa Y; Yoshimoto S; Miura K; Shiotani A; Yokoyama J; Sugasawa M; Moriyama-Kita M; Endo K; Yoshizaki T
PLoS One; 2015; 10(12):e0144056. PubMed ID: 26630663
[TBL] [Abstract][Full Text] [Related]
28. Angiogenic responses of vascular endothelial growth factors in periadventitial tissue.
Bhardwaj S; Roy H; Gruchala M; Viita H; Kholova I; Kokina I; Achen MG; Stacker SA; Hedman M; Alitalo K; Ylä-Herttuala S
Hum Gene Ther; 2003 Oct; 14(15):1451-62. PubMed ID: 14577925
[TBL] [Abstract][Full Text] [Related]
29. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma.
White JD; Hewett PW; Kosuge D; McCulloch T; Enholm BC; Carmichael J; Murray JC
Cancer Res; 2002 Mar; 62(6):1669-75. PubMed ID: 11912138
[TBL] [Abstract][Full Text] [Related]
30. Different role of COX-2 and angiogenesis in canine inflammatory and non-inflammatory mammary cancer.
Clemente M; Sánchez-Archidona AR; Sardón D; Díez L; Martín-Ruiz A; Caceres S; Sassi F; Dolores Pérez-Alenza M; Illera JC; Dunner S; Peña L
Vet J; 2013 Aug; 197(2):427-32. PubMed ID: 23489848
[TBL] [Abstract][Full Text] [Related]
31. Endothelin-1 cooperates with hypoxia to induce vascular-like structures through vascular endothelial growth factor-C, -D and -A in lymphatic endothelial cells.
Garrafa E; Caprara V; Di Castro V; Rosanò L; Bagnato A; Spinella F
Life Sci; 2012 Oct; 91(13-14):638-43. PubMed ID: 22552325
[TBL] [Abstract][Full Text] [Related]
32. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of lymphatic metastasis in neuroblastoma by a novel neutralizing antibody to vascular endothelial growth factor-D.
Kashima K; Watanabe M; Satoh Y; Hata J; Ishii N; Aoki Y
Cancer Sci; 2012 Dec; 103(12):2144-52. PubMed ID: 22937829
[TBL] [Abstract][Full Text] [Related]
34. Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis.
Matsumoto M; Roufail S; Inder R; Caesar C; Karnezis T; Shayan R; Farnsworth RH; Sato T; Achen MG; Mann GB; Stacker SA
Clin Exp Metastasis; 2013 Aug; 30(6):819-32. PubMed ID: 23591595
[TBL] [Abstract][Full Text] [Related]
35. Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis.
Kim DG; Jin Y; Jin J; Yang H; Joo KM; Lee WS; Shim SR; Kim SW; Yoo J; Lee SH; Yoo JS; Nam DH
MAbs; 2015; 7(6):1195-204. PubMed ID: 26325365
[TBL] [Abstract][Full Text] [Related]
36. Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects.
Detoraki A; Staiano RI; Granata F; Giannattasio G; Prevete N; de Paulis A; Ribatti D; Genovese A; Triggiani M; Marone G
J Allergy Clin Immunol; 2009 May; 123(5):1142-9, 1149.e1-5. PubMed ID: 19275959
[TBL] [Abstract][Full Text] [Related]
37. The role of vascular endothelial growth factors and their receptors in malignant melanomas.
Brychtova S; Bezdekova M; Brychta T; Tichy M
Neoplasma; 2008; 55(4):273-9. PubMed ID: 18505336
[TBL] [Abstract][Full Text] [Related]
38. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy.
Underiner TL; Ruggeri B; Gingrich DE
Curr Med Chem; 2004 Mar; 11(6):731-45. PubMed ID: 15032727
[TBL] [Abstract][Full Text] [Related]
39. New insights on the role of vascular endothelial growth factor in biliary pathophysiology.
Mariotti V; Fiorotto R; Cadamuro M; Fabris L; Strazzabosco M
JHEP Rep; 2021 Jun; 3(3):100251. PubMed ID: 34151244
[TBL] [Abstract][Full Text] [Related]
40. Differential mRNA and tissue expression of lymphangiogenic growth factors (VEGF-C and -D) and their receptor (VEGFR-3) during tail regeneration in a gecko.
Blacker HA; Orgeig S
J Comp Physiol B; 2012 Jan; 182(1):109-26. PubMed ID: 21800152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
